Bewilligte Forschungsprojekte 2015

Forschungsprojekte 2015
Projets de recherche 2015
Unterstützt von: / Soutenus par:
Grundlagenforschung / Recherche fondamentale
Gesuchsteller/In
Candidat/e
Projektnummer
Projekttitel
Numéro du projet
Titre du projet
Dauer
(Monate)
Durée
(mois)
Betrag
(CHF)
Montant
(CHF)
Ballmer-Hofer Kurt, Prof. Dr.
Forschungsbereich Biologie und
Chemie (BIO)
Paul Scherrer Institut (PSI)
5232 Villigen
KLS 3569-02-2015
Role of VEGF receptor signalling in primary
and metastatic tumour growth and preclinical
evaluation of novel allosteric VEGFR-2
inhibitors
6
76 550.–
Bertoni Francesco, Dr.
Lymphoma and Genomics
Research Program
IOR Institute of Oncology
Research
6500 Bellinzona
KLS 3580-02-2015
Characterization of FLI1 as an oncogene and
therapeutic target in diffuse large B-cell
lymphomas
36
359 800.–
Hantschel Oliver, Prof.
EPFL SV ISREC UPHAN
EPF de Lausanne
1015 Lausanne
KLS 3595-02-2015
Identification and targeting of allosteric
regulatory sites in oncogenic cytoplasmic
tyrosine kinases
36
374 750.–
Müller Anne, Prof. Dr.
Institut für Molekulare
Krebsforschung
Universität Zürich (UZH)
8057 Zürich
KLS 3612-02-2015
The haematopoietic oncoprotein FoxP1
promotes tumour cell survival in diffuse large
B-cell lymphoma: identification of FoxP1
target genes and their relevance for patient
stratification and prognostication
18
164 900.–
Theurillat Jean-Philippe,
Prof. Dr.
IOR Institute of Oncology
Research
6500 Bellinzona
KLS 3654-02-2015
Role of TRIM24 in prostate cancer initiation
and progression
24
247 200.–

Klinische Forschung / Recherche clinique
Gesuchsteller/In
Candidat/e
Projektnummer
Projekttitel
Numéro du projet
Titre du projet
Dauer
(Monate)
Durée
(mois)
Betrag
(CHF)
Montant
(CHF)
Ammann Roland A.,
Prof. Dr. med.
Pediatric Hematology/Oncology
Department of Pediatrics
University of Bern
3010 Bern
KLS 3645-02-2015
SPOG 2015 FN definition a Swiss Paediatric
Oncology Group (SPOG) initiated multicentre
open-label randomized controlled multiple
crossover non-inferiority trial on safety of a
high versus low temperature limit defining
fever in paediatric patients with cancer at risk
for fever in chemotherapy-induced
neutropenia (FN)
48
327 800.–
Güller Ulrich, Prof. Dr. med.
Medical Oncology & Hematology
Kantonsspital St. Gallen (KSSG)
9007 St. Gallen
KLS 3596-02-2015
SAKK 41/13 adjuvant aspirin treatment in
PIK3CA mutated colon cancer patients. A
randomized, double-blinded, placebo-
controlled, phase III trial
36
351 650.–
Hemkens Lars, Dr. med.
Institute for Clinical Epidemiology
and Biostatistics
University Hospital Basel
4031 Basel
KLS 3587-02-2015
Clinical decision-making with novel cancer
treatments: a meta-epidemiological study on
the post-approval generation of clinical
evidence
36
166 000.–
Rinaldi Andrea, Dr.
Functional Genomics and
Lymphoma Group
IOR Institute of Oncology
Research
6500 Bellinzona
KLS 3636-02-2015
An international phase III multicentre,
randomized study with lenalidomide
maintenance versus observation after
intensified induction regimen containing
rituximab followed by high dose
chemotherapy and autologous stem cell
transplantation as first line treatment in adult
patients with advanced mantle cell
lymphoma: identification of DNA and
methylation changes associated with the
clinical outcome
24
115 800.–
Terracciano Luigi M., Prof. Dr.
Molecular Pathology Division
University of Basel
4003 Basel
KLS 3639-02-2015
Genetic determinants for progression from
cirrhosis to hepatocellular carcinoma
36
365 000.–

Psychosoziale Forschung / Recherche psychosociale
Gesuchsteller/In
Candidat/e
Projektnummer
Projekttitel
Numéro du projet
Titre du projet
Dauer
(Monate)
Durée
(mois)
Betrag
(CHF)
Montant
(CHF)
Barth Jürgen, PD Dr. phil.
Institute for Complementary and
Integrative Medicine
University Hospital Zürich
8006 Zürich
KLS 3564-02-2015
Feasibility of a mind-body medicine mobile
app for cancer patients
36
199 550.–
Epidemiologische Forschung / Recherche épidémiologie
Gesuchsteller/In
Candidat/e
Projektnummer
Projekttitel
Numéro du projet
Titre du projet
Dauer
(Monate)
Durée
(mois)
Betrag
(CHF)
Montant
(CHF)
Bochud Murielle, Prof. Dr. med.
Division des Maladies
Chroniques - Institut Universitaire
de Médecine Sociale et
Préventive
Centre hospitalier universitaire
vaudois (CHUV)
1010 Lausanne
KLS 3644-02-2015
Dietary habits, nutrition and risk of late
effects after childhood cancer
36
290 200.–

Stipendien 2015
Bourses 2015
Unterstützt von: / Soutenus par:
Gesuchsteller/In
Candidat/e
Projektnummer
Projekttitel
Numéro du projet
Titre du projet
Dauer
(Monate)
Durée
(mois)
Betrag
(CHF)
Montant
(CHF)
Böttcher Steffen, Dr. med.
Division of Hematology
UniversitätsSpital Zürich (USZ)
8091 Zürich
BIL KLS 3625-02-2015
Generation of mouse models of acute
myeloid leukaemia for the identification of
genotype-specific therapeutic targets
Destination: Brigham and Women’s Hosital,
Harvard Medical School, Dana-Farber
Cancer Institut, Boston, USA
12
80 800.–
Schubert Adrian Daniel,
Dr. med.
Universitätsklinik für Hals-,
Nasen- und Ohrenkrankheiten
(HNO)
Inselspital Bern
3012 Bern
BIL KLS 3649-02-2015
A prospective study evaluating clinical
outcomes using plasma and salivary ctDNA
in HNSCC
Destination: Division of Head and Neck
Cancer Research, Department of
Otolaryngology, Johns Hopkins Cancer
Research Build II, Baltimore, USA
18
95 050.–

Forschungsprojekte 2015
Projets de recherche 2015
Unterstützt von: / Soutenus par:
Grundlagenforschung / Recherche fondamentale
Gesuchsteller/In
Candidat/e
Projektnummer
Projekttitel
Numéro du projet
Titre du projet
Dauer
(Monate)
Durée
(mois)
Betrag
(CHF)
Montant
(CHF)
Basler Konrad, Prof.
Institut für Molekulare Biologie
Universität Zürich (UZH)
8057 Zürich
KFS 3572-02-2015
Assessment of the therapeutic potential of
targeting Wnt ligand production and β-
catenin activity in treating colon cancer
36
360 350.–
Bentires-Alj Mohamed, Prof. Dr.
Friedrich Miescher Institut für
biomedizinische Forschung (FMI)
4058 Basel
KFS 3571-02-2015
Targeting the phosphatase SHP2 and
blocking macrophages in metastatic breast
cancer
36
357 150.–
De Libero Gennaro, Prof.
Department of Biomedicine
Universität Basel
4031 Basel
KFS 3730-08-2015
A novel population of human MR1-restricted
T-cells in anti-tumour immunity
36
365 100.–
Frew Ian, Prof. Dr.
Physiologisches Institut
Universität Zürich (UZH)
8057 Zürich
KFS 3693-08-2015
Development of mouse models and
identification of therapies for renal
angiomyolipoma
36
375 000.–
Giachino Claudio, Dr.
Department of Biomedicine
University of Basel
4058 Basel
KFS 3600-02-2015
A novel tumour suppressor function of Notch
receptors in glioma
36
351 250.–
Gilliet Michel, Prof.
Dermatology
Centre hospitalier universitaire
vaudois (CHUV)
1011 Lausanne
KFS 3652-02-2015
Spontaneous and therapeutic STING
activation in the tumour microenvironment of
melanoma
36
370 800.–
Gorr Thomas, PD Dr.
Institute of Veterinary Physiology
University of Zurich (UZH)
8057 Zurich
KFS 3692-08-2015
Role of myoglobin in the tumourigenesis of
p53 wild type and deficient breast cancers
36
242 450.–